Power Law company profile

Barinthus Biotherapeutics

Biotech & Life Sciences · Harwell, United Kingdom · Founded 2016 · IPO 2021 Colt

T cell immunotherapeutics for chronic infectious diseases

Revenue

$45M

Latest reported FY

EBITDA

$869K

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Investors

13 investors on Barinthus Biotherapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage

HongShan

Sequoia

Oxford Science Enterprises

Neptune Ventures

Series B+ 8 investors entered at this stage

Oxford University Innovation

GeneMatrix

University of Oxford

Tencent

Gilead Sciences

Future Planet Capital

M&G Investments

Korea Investment Partners

Global footprint

Where Barinthus Biotherapeutics has talent and traffic

Workforce by country

🇬🇧 United Kingdom · Harwell HQ

Book a demo for the full country breakdown

Web traffic by country

2.9K monthly visits
across markets

🇬🇧 United Kingdom65.5%

🇺🇸 United States37.9%

Top 2 markets shown

Market sentiment

What the market is saying about Barinthus Biotherapeutics

An AI-synthesized read of the highest-engagement posts about Barinthus Biotherapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Barinthus Biotherapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles